Carlson, Josh J.
Walton, Surrey M.
Basu, Anirban
Chapman, Richard H.
Campbell, Jonathan D.
McQueen, R. Brett
Pearson, Steven D.
Touchette, Daniel R.
Veenstra, David
Whittington, Melanie D.
Ollendorf, Daniel A. http://orcid.org/0000-0001-6016-8129
Article History
First Online: 5 September 2019
Compliance with Ethical Standards
:
: No sources of funding were used to develop this manuscript.
: The work described in the manuscript is relevant to Dr. Carlson’s current grant from ICER. Dr. Carlson has carried out consulting work with pharmaceutical companies that were included in the work described in the manuscript. Some of the work described in the manuscript is relevant to Dr. Walton’s and Dr. Touchette’s current contract-related funding from ICER. Specific transparency efforts related to a project with ICER described here that involved Dr. Walton and Dr. Touchette were funded by Allergan, Amgen, and Teva Pharmaceuticals. Drs. Campbell, McQueen, and Whittington have received project-related funding from ICER. Drs Basu and Veenstra work at the University of Washington, which has a contract with ICER. Drs Chapman and Pearson are employees, and Dr. Ollendorf is a former employee, of ICER, whose efforts are funded by the Laura and John Arnold Foundation and the California Healthcare Foundation. Over the past 3 years, ICER as an organization has received membership dues—unrelated to these activities—from a variety of payer and life science companies.